T1	Age 18 28	7-year-old
T2	Personal_background 29 36	Italian
T3	Sex 37 40	boy
T4	History 41 94	born after an uneventful gestation of normal duration
T5	Date 96 119	At the age of 16 months
E1	Date:T5 
T6	Clinical_event 124 133	presented
E2	Clinical_event:T6 
T7	Sign_symptom 160 168	enlarged
E3	Sign_symptom:T7 
T8	Biological_structure 169 176	abdomen
R1	MODIFY Arg1:T8 Arg2:E3	
T9	Detailed_description 141 159	clinically evident
R2	MODIFY Arg1:T9 Arg2:E3	
T10	Clinical_event 185 193	referred
E4	Clinical_event:T10 
T11	Nonbiological_location 198 221	oncological examination
R3	MODIFY Arg1:T11 Arg2:E4	
T12	Sign_symptom 246 252	anemia
E5	Sign_symptom:T12 
T13	Sign_symptom 254 270	thrombocytopenia
E6	Sign_symptom:T13 
T14	Sign_symptom 276 288	splenomegaly
E7	Sign_symptom:T14 
T15	Diagnostic_procedure 304 310	biopsy
E8	Diagnostic_procedure:T15 
T16	Biological_structure 292 303	bone marrow
R4	MODIFY Arg1:T16 Arg2:E8	
T17	Sign_symptom 336 346	foam cells
E9	Sign_symptom:T17 
T18	Disease_disorder 374 399	lysosomal storage disease
E10	Disease_disorder:T18 
T19	Diagnostic_procedure 401 420	Biochemical testing
E11	Diagnostic_procedure:T19 
T20	Diagnostic_procedure 448 464	acid phosphatase
E12	Diagnostic_procedure:T20 
T21	Lab_value 466 475	47.8 IU/L
R5	MODIFY Arg1:T21 Arg2:E12	
T22	Lab_value 430 438	elevated
R6	MODIFY Arg1:T22 Arg2:E12	
T23	Diagnostic_procedure 505 529	chitotriosidase activity
E13	Diagnostic_procedure:T23 
R7	MODIFY Arg1:T22 Arg2:E13	
T24	Lab_value 531 550	508 nmol/mg protein
R8	MODIFY Arg1:T24 Arg2:E13	
T25	Diagnostic_procedure 612 637	beta-glucosidase activity
E14	Diagnostic_procedure:T25 
T26	Lab_value 604 611	reduced
R9	MODIFY Arg1:T26 Arg2:E14	
T27	Lab_value 639 656	2 nmol/mg/protein
R10	MODIFY Arg1:T27 Arg2:E14	
T28	Diagnostic_procedure 699 717	Molecular analysis
E15	Diagnostic_procedure:T28 
T29	Disease_disorder 829 832	NGD
E16	Disease_disorder:T29 
#1	AnnotatorNotes E16	neuronopathic Gaucher disease
T30	Sign_symptom 742 767	mutations in the GBA gene
E17	Sign_symptom:T30 
T31	Detailed_description 736 741	L444P
T32	Detailed_description 725 735	homozygous
R11	MODIFY Arg1:T31 Arg2:E17	
R12	MODIFY Arg1:T32 Arg2:E17	
T33	Therapeutic_procedure 852 855	ERT
E18	Therapeutic_procedure:T33 
#2	AnnotatorNotes E18	Enzyme replacement therapy
T34	Dosage 871 892	60 U/kg every 2 weeks
R13	MODIFY Arg1:T34 Arg2:E18	
T35	Date 893 916	at the age of 18 months
E19	Date:T35 
T36	Date 959 975	age of 30 months
E20	Date:T36 
T37	Therapeutic_procedure 999 1002	ERT
E21	Therapeutic_procedure:T37 
T38	Therapeutic_procedure 1008 1011	SRT
E22	Therapeutic_procedure:T38 
#3	AnnotatorNotes E22	substrate reduction therapy
T39	Medication 1017 1026	miglustat
E23	Medication:T39 
R14	SUB_PROCEDURE Arg1:E23 Arg2:E22	
T40	Medication 1215 1224	miglustat
E24	Medication:T40 
T41	Detailed_description 1229 1282	adjusted according to the patient’s body surface area
R15	MODIFY Arg1:T41 Arg2:E24	
T42	Dosage 1466 1490	100 mg three times daily
T43	Date 1492 1505	after 1 month
E25	Date:T43 
R16	MODIFY Arg1:T42 Arg2:E24	
T44	Therapeutic_procedure 1590 1611	dietary modifications
E26	Therapeutic_procedure:T44 
T45	Date 1507 1526	From 2 weeks before
E27	Date:T45 
T46	Medication 1536 1545	miglustat
E28	Medication:T46 
T47	Detailed_description 1613 1681	avoiding high intake of carbohydrate-containing food in single meals
R17	MODIFY Arg1:T47 Arg2:E26	
T48	Sign_symptom 1836 1844	diarrhea
E29	Sign_symptom:T48 
T49	Severity 1819 1823	mild
R18	MODIFY Arg1:T49 Arg2:E29	
T50	Medication 1862 1871	miglustat
E30	Medication:T50 
T51	Detailed_description 1694 1750	foods high in disaccharides, such as sucrose and maltose
R19	MODIFY Arg1:T51 Arg2:T47	
T52	Lab_value 1887 1928	decreased in frequency/severity over time
R20	MODIFY Arg1:T52 Arg2:E29	
T53	Sign_symptom 2012 2024	splenomegaly
E31	Sign_symptom:T53 
A1	TREND E31 DEC
T54	Diagnostic_procedure 2056 2076	hematological values
E32	Diagnostic_procedure:T54 
T55	Lab_value 2039 2052	normalization
R21	MODIFY Arg1:T55 Arg2:E32	
T56	Diagnostic_procedure 2081 2126	plasma angiotensin-converting enzyme activity
E33	Diagnostic_procedure:T56 
R22	MODIFY Arg1:T55 Arg2:E33	
T57	Diagnostic_procedure 2138 2160	Plasma chitotriosidase
E34	Diagnostic_procedure:T57 
T58	Frequency 2223 2237	every 6 months
R23	MODIFY Arg1:T58 Arg2:E34	
T59	Clinical_event 2245 2254	follow-up
E35	Clinical_event:T59 
T60	Lab_value 2273 2290	initial reduction
T61	Lab_value 2348 2366	sustained decrease
R24	MODIFY Arg1:T60 Arg2:E34	
R25	MODIFY Arg1:T61 Arg2:E34	
T62	Detailed_description 2291 2313	after the start of ERT
T63	Detailed_description 2367 2398	after commencement of miglustat
R26	MODIFY Arg1:T62 Arg2:T60	
R27	MODIFY Arg1:T63 Arg2:T61	
T64	Clinical_event 2439 2447	followed
E36	Clinical_event:T64 
T65	Detailed_description 2448 2490	according to recommended guidelines for GD
R28	MODIFY Arg1:T65 Arg2:E36	
T66	Diagnostic_procedure 2517 2541	neurological examination
E37	Diagnostic_procedure:T66 
T67	Diagnostic_procedure 2552 2582	evaluation of ocular movements
E38	Diagnostic_procedure:T67 
T68	Diagnostic_procedure 2588 2613	psychological evaluations
E39	Diagnostic_procedure:T68 
T69	Frequency 2614 2631	every 6–12 months
R29	MODIFY Arg1:T69 Arg2:E39	
T70	Duration 2644 2651	5 years
E40	Duration:T70 
T71	Therapeutic_procedure 2655 2674	combination therapy
E41	Therapeutic_procedure:T71 
T72	Clinical_event 2679 2688	follow-up
E42	Clinical_event:T72 
R30	MODIFY Arg1:E40 Arg2:E41	
R31	MODIFY Arg1:E40 Arg2:E42	
T73	Sign_symptom 2728 2751	neurological impairment
E43	Sign_symptom:T73 
A2	POLARITY E43 NEG
T74	Date 2759 2772	February 2016
E44	Date:T74 
T75	Sign_symptom 2799 2815	epileptic crises
E45	Sign_symptom:T75 
A3	POLARITY E45 NEG
T76	Sign_symptom 2837 2857	clinical performance
E46	Sign_symptom:T76 
T77	Activity 2862 2873	cooperation
E47	Activity:T77 
T78	Diagnostic_procedure 2890 2916	muscular tone and trophism
E48	Diagnostic_procedure:T78 
T79	Lab_value 2885 2889	good
R32	MODIFY Arg1:T79 Arg2:E48	
T80	Diagnostic_procedure 2925 2933	reflexes
E49	Diagnostic_procedure:T80 
T81	Lab_value 2918 2924	normal
R33	MODIFY Arg1:T81 Arg2:E49	
T82	Sign_symptom 2948 2961	hyperreflexia
E50	Sign_symptom:T82 
T83	Severity 2941 2947	slight
R34	MODIFY Arg1:T83 Arg2:E50	
T84	Biological_structure 2969 2973	legs
R35	MODIFY Arg1:T84 Arg2:E50	
T85	Diagnostic_procedure 2990 3002	Romberg sign
E51	Diagnostic_procedure:T85 
T86	Lab_value 2981 2989	negative
R36	MODIFY Arg1:T86 Arg2:E51	
T87	Diagnostic_procedure 3008 3033	toe and heel deambulation
E52	Diagnostic_procedure:T87 
T88	Lab_value 3038 3044	normal
R37	MODIFY Arg1:T88 Arg2:E52	
T89	Diagnostic_procedure 3061 3079	ocular evaluations
E53	Diagnostic_procedure:T89 
T90	Sign_symptom 3104 3140	saccadic movement velocity reduction
E54	Sign_symptom:T90 
A4	POLARITY E54 NEG
T91	Diagnostic_procedure 3152 3176	visual evoked potentials
E55	Diagnostic_procedure:T91 
R38	SUB_PROCEDURE Arg1:E55 Arg2:E53	
T92	Lab_value 3145 3151	normal
R39	MODIFY Arg1:T92 Arg2:E55	
T93	Diagnostic_procedure 3192 3216	auditory brain responses
E56	Diagnostic_procedure:T93 
T94	Lab_value 3227 3233	normal
R40	MODIFY Arg1:T94 Arg2:E56	
T95	Sign_symptom 3276 3296	cognitive impairment
E57	Sign_symptom:T95 
A5	POLARITY E57 NEG
T96	Activity 3319 3334	attended school
E58	Activity:T96 
T97	Detailed_description 3340 3356	good performance
R41	MODIFY Arg1:T97 Arg2:E58	
T98	Detailed_description 3309 3318	regularly
R42	MODIFY Arg1:T98 Arg2:E58	
T99	Date 3357 3381	since the age of 5 years
E59	Date:T99 
*	OVERLAP E1 E2 E3
R43	BEFORE Arg1:E3 Arg2:E4	
*	OVERLAP E4 E5 E6 E7 E8 E9 E10 E11 E12 E13 E14 E15 E17 E16
R44	BEFORE Arg1:E16 Arg2:E18	
*	OVERLAP E18 E19
R45	BEFORE Arg1:E19 Arg2:E20	
*	OVERLAP E20 E21 E22
R46	BEFORE Arg1:E22 Arg2:E24	
*	OVERLAP E24 E25
R47	AFTER Arg1:E25 Arg2:E27	
*	OVERLAP E27 E28 E26
R48	BEFORE Arg1:E26 Arg2:E29	
*	OVERLAP E29 E30
R49	BEFORE Arg1:E30 Arg2:E31	
*	OVERLAP E31 E32 E33
R50	AFTER Arg1:E33 Arg2:E34	
R51	BEFORE Arg1:E34 Arg2:E35	
R52	BEFORE Arg1:E35 Arg2:E36	
*	OVERLAP E36 E37 E38 E39
R53	MODIFY Arg1:T69 Arg2:E38	
R54	MODIFY Arg1:T69 Arg2:E37	
R55	BEFORE Arg1:E39 Arg2:E40	
*	OVERLAP E40 E41 E42 E43
R56	BEFORE Arg1:E43 Arg2:E44	
*	OVERLAP E44 E45 E46 E47 E48 E49 E50 E51 E52 E53 E54 E56 E57 E58 E59
